Literature DB >> 26519842

Blood donors screening for blood born viruses in Poland.

Piotr Grabarczyk1, Aneta Kopacz1, Ewa Sulkowska1, Dorota Kubicka-Russel1, Maria Mikulska1, Ewa Brojer1, Magdalena Łętowska1.   

Abstract

Blood donor screening of viral markers in Poland is based on serologic testing for anti-HCV, HBsAg, anti-HIV1/2 (chemiluminescence tests) and on nucleic acid testing (NAT) for RNA HCV, RNA HIV-1 and DNA HBV performed in minipools of 6 with real-time PCR (MPX 2.0 test on cobas s201) or with TMA in individual donations (Ultrio Plus or Ultrio Elite). Donors of plasma for anti-D and anti-HBs production are tested for parvovirus B19 DNA. Before implementation tests and equipment are evaluated at the Institute of Hematology and Transfusion Medicine (IHTM). The last 20 years witnessed a decreasing trend for HBsAg in both first time and repeat donors (1%-0.3% and 0.1%-0.02% respectively). Prevalence of anti-HCV repeat reactive results was stable and oscillated around 0.8% for first time donors and 0.2% for repeat donors. Elevated prevalence of seropositive HIV infected donors was recently observed (7.5-9 cases/100,000 donors). Since respective molecular markers implementation HCV RNA was detected on average in 1/119,235 seronegative donations, HIV RNA in 1/783,821 and HBV DNA in 1/61,047. HBV NAT yields were mostly occult hepatitis B (1/80,248); window period cases were less frequent (1/255,146). The efficiency of HBV DNA detection depends on the sensitivity of the HBV DNA screening system.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26519842

Source DB:  PubMed          Journal:  Przegl Epidemiol        ISSN: 0033-2100


  5 in total

1.  What weighs more-low compliance with self-deferral or minor medical procedures? Explaining the high rate of hepatitis C virus window-period donations in Poland.

Authors:  Michal Czerwinski; Piotr Grabarczyk; Malgorzata Stepien; Dorota Kubicka-Russel; Katarzyna Tkaczuk; Ewa Brojer; Magdalena Rosinska
Journal:  Transfusion       Date:  2017-05-28       Impact factor: 3.157

2.  Human Intramuscular Hyperimmune Gamma Globulin (hIHGG) Anti-SARS-CoV-2-Characteristics of Intermediates and Final Product.

Authors:  Elzbieta Lachert; Joanna Lasocka; Artur Bielawski; Ewa Sulkowska; Katarzyna Guz; Krzysztof Pyrc; Agnieszka Dabrowska; Agata Wawryniuk-Malmon; Magdalena Letowska; Krzysztof Tomasiewicz; Piotr Grabarczyk
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

3.  Co-Infection of the Hepatitis C Virus With Other Blood-Borne and Hepatotropic Viruses Among Hemophilia Patients in Poland.

Authors:  Marta Kucharska; Malgorzata Inglot; Aleksandra Szymczak; Weronika Rymer; Malgorzata Zalewska; Krzysztof Malyszczak; Urszula Zaleska-Dorobisz; Malgorzata Kuliszkiewicz-Janus
Journal:  Hepat Mon       Date:  2016-07-23       Impact factor: 0.660

4.  Prevalence of HBV DNA among 20 million seronegative blood donations in China from 2010 to 2015.

Authors:  Chao Liu; Le Chang; Huimin Ji; Fei Guo; Kuo Zhang; Guigao Lin; Rui Zhang; Jinming Li; Lunan Wang
Journal:  Sci Rep       Date:  2016-11-11       Impact factor: 4.379

5.  Significant proportion of acute hepatitis B in Poland in 2010-2014 attributed to hospital transmission: combining surveillance and public registries data.

Authors:  Małgorzata Stępień; Karolina Zakrzewska; Magdalena Rosińska
Journal:  BMC Infect Dis       Date:  2018-04-10       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.